A new treatment called crosslinking or CXL to stop progressive vision loss from keratoconus is now under FDA clinical protocol at the Mercy Center for Corrective Eye Surgery. Mercy is the first and only crosslinking FDA clinical protocol center in Illinois or Wisconsin. The treatment, consisting of application of riboflavin eye drops and a weak dose of ultraviolet light similar to outside in the shade on a summer day, to the affected cornea. The treatment was developed in Switzerland in 1998 and is in practice widely outside the U.S. (Read More)